Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Stefan Sleijfer"'
Publikováno v:
European Journal of Cancer, 138, 54-56. Elsevier Ltd.
Autor:
Astrid A M van der Veldt, Esther Oomen-de Hoop, Stijn L.W. Koolen, Daan P. Hurkmans, Ilse den Besten, Edwin A. Basak, Marco W.J. Schreurs, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Annemarie J.M. Wijkhuijs, Reno Debets, Stefan Sleijfer, Sander Bins
Publikováno v:
European Journal of Cancer, 109, 12-20. Elsevier Ltd.
Introduction Nivolumab treatment is subject to large interpatient variability in both efficacy and toxicity, which may partly be explained by differences in nivolumab exposure. Exposure–response relationships in regular healthcare have not been ext
Autor:
Carin A. Uyl-de Groot, Stefan Sleijfer, Dirk J. Grünhagen, Evalyn E. A. P. Mulder, Astrid A M van der Veldt
Publikováno v:
European Journal of Cancer, 157, 306-307. Elsevier Ltd.
As an increasing number of patients with melanoma is being treated with adjuvant systemic therapy, there is a growing need for an effective and efficient follow-up strategy to address issues such as radiation burden, increasing costs, and limited res
Autor:
Pauline A J Mendelaar, Roderick R. Dulfer, Bronno van der Holt, Stefan Sleijfer, Paul Hamberg, Ron H.J. Mathijssen, Karel Eechoute, Jacqueline S. L. Kloth, Erik A.C. Wiemer, Wim H. J. Kruit
Publikováno v:
European Journal of Cancer, 56, 101-106. Elsevier Ltd.
Aim of the study As a rise in mean corpuscular volume (MCV) of the erythrocyte is frequently seen during treatment with imatinib and sunitinib, we investigated whether macrocytosis (MCV > 100 fl) also occurs as a class effect in other tyrosine kinase
Autor:
Jean-Charles Soria, Claire Aerts, Gerd Munzert, Stefan Sleijfer, Jean-Pascal Machiels, Jan Bogaerts, Etienne Brain, Holger Fritsch, Gertraud Hanft, Christel Fontaine, Jérôme Rapion, Isabelle Ray-Coquard, Anouk Allgeier, Denis Lacombe, Pascal Wolter, Patrick Schöffski, Jean-Yves Blay, Jacques De Greve
Publikováno v:
European Journal of Cancer, 46(12), 2206-2215. Elsevier Ltd.
Aims: BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1. We performed a multi-centre, multi-tumour phase II trial to investigate the efficacy, safety and pharmacokinetics of BI 2536 in five solid tumour types. Patients